New drug aims to preserve muscle during weight loss in obesity trial

NCT ID NCT06445075

First seen Jan 24, 2026 · Last updated May 16, 2026 · Updated 21 times

Summary

This study tested a drug called apitegromab in 102 overweight or obese adults who were also taking a GLP-1 medication (like Ozempic or Wegovy). The goal was to see if adding apitegromab helps preserve lean muscle mass while losing weight. Participants received either the drug or a placebo for 24 weeks, and body composition was measured with X-ray scans.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AdventHealth Translational Research Institute

    Orlando, Florida, 32804, United States

  • Alliance for Multispecialty Research, LLC

    Norman, Oklahoma, 73069, United States

  • Apex Mobile Clinical Research

    Bellaire, Texas, 77401, United States

  • Clinical Trials of Texas, LLC dba Flourish Research

    San Antonio, Texas, 78229, United States

  • Great Lakes Clinical Trials, LLC d/b/a Flourish Research

    Chicago, Illinois, 60640, United States

  • ProSciento CRU

    Chula Vista, California, 91911, United States

  • Tandem Clinical Research GI, LLC

    Marrero, Louisiana, 70072, United States

Conditions

Explore the condition pages connected to this study.